On November 4, 2020 Protagonist Therapeutics, Inc. (NASDAQ: PTGX) reported the acceptance of one oral and four poster presentations at the American Society for Hematology (ASH) (Free ASH Whitepaper) annual meeting, taking place in a virtual format December 5-8, 2020 (Press release, Protagonist, NOV 4, 2020, View Source [SID1234569903]). The abstract data includes results as of early August 2020 from the ongoing Phase 2 study of PTG-300 in the treatment of polycythemia vera. Additional updated data from the study will be available during presentations at the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This year’s ASH (Free ASH Whitepaper) meeting provides an opportunity for Protagonist to share detailed findings of its PTG-300 hepcidin mimetic program for polycythemia vera (PV) at a major medical conference for the first time," commented Dinesh V. Patel, Ph.D., Protagonist President and Chief Executive Officer. "We look forward to presenting updated results from our ongoing Phase 2 PTG-300 proof-of-concept PV study at the conference. We will also present an analysis of real world patient data and potential unmet need in PV, as well as promising preclinical findings with a new oral hepcidin mimetic peptide. As a non-cytoreductive treatment option based on the activity of a natural hormone, PTG-300 has truly transformative potential for PV patients and we look forward to advancing PTG-300 on the path toward regulatory approval as efficiently as possible."

Oral presentation:

1) Title: PTG-300 Eliminates the Need for Therapeutic Phlebotomy in Both Low and High-Risk Polycythemia Vera Patients (Abstract #482)
Session: 634. Myeloproliferative Syndromes: Clinical: Clinical Trials in Polycythemia Vera
Session Date: Sunday, December 6, 2020
Presentation Time: 2:45 p.m. PST
Presenter: Marina Kremyanskaya, M.D., Ph.D., Icahn School of Medicine at Mount Sinai

Poster presentations:

2) Title: Hepcidin Mimetic (PTG-300) Reverses Iron Deficiency While Controlling Hematocrit in Polycythemia Vera Patients (Abstract #1689)
Session: 102. Regulation of Iron Metabolism: Poster II
Date: Sunday, December 6, 2020
Presenter: Yelena Ginzburg, M.D., Icahn School of Medicine at Mount Sinai

3) Title: Real-World Treatments and Thrombotic Events in Polycythemia Vera Patients: A Retrospective Analysis between 2018-2019 in US Population (Abstract #2998)
Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster III
Date: Monday, December 7, 2020
Presenter: Srdan Verstovsek, M.D., Ph.D., MD Anderson Cancer Center

4) Title: Mechanism of Systemic Iron Regulation and Hematocrit Control by Hepcidin Peptidomimetics in Pre-Clinical Models (Abstract #2594)
Session: 102. Regulation of Iron Metabolism: Poster III
Date: Monday, December 7, 2020
Presenter: Roopa Taranath, Ph.D., Protagonist Therapeutics

5) Title: Hepcidin Peptidomimetics – Oral Efficacy in Pre-Clinical Disease Model of Iron Overload (Abstract #2592)
Session: 102. Regulation of Iron Metabolism: Poster III
Date: Monday, December 7, 2020
Presenter: Roopa Taranath, Ph.D., Protagonist Therapeutics

Abstracts are available via the ASH (Free ASH Whitepaper) meeting website at View Source